Literature DB >> 26958158

An Interactive User Interface for Drug Labeling to Improve Readability and Decision-Making.

Hamed Abedtash1, Jon D Duke2.   

Abstract

FDA-approved prescribing information (also known as product labeling or labels) contain critical safety information for health care professionals. Drug labels have often been criticized, however, for being overly complex, difficult to read, and rife with overwarning, leading to high cognitive load. In this project, we aimed to improve the usability of drug labels by increasing the 'signal-to-noise ratio' and providing meaningful information to care providers based on patient-specific comorbidities and concomitant medications. In the current paper, we describe the design process and resulting web application, known as myDrugLabel. Using the Structured Product Label documents as a base, we describe the process of label personalization, readability improvements, and integration of diverse evidence sources, including the medical literature from PubMed, pharmacovigilance reports from FDA adverse event reporting system (FAERS), and social media signals directly into the label.

Entities:  

Mesh:

Year:  2015        PMID: 26958158      PMCID: PMC4765573     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  4 in total

1.  Drug labeling revisions-guaranteed to fail?

Authors:  R L Woosley
Journal:  JAMA       Date:  2000-12-20       Impact factor: 56.272

2.  Highlights and a hidden hazard--the FDA's new labeling regulations.

Authors:  Jerry Avorn; William Shrank
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

3.  A quantitative analysis of adverse events and "overwarning" in drug labeling.

Authors:  Jon Duke; Jeff Friedlin; Patrick Ryan
Journal:  Arch Intern Med       Date:  2011-05-23

4.  Requirements on content and format of labeling for human prescription drug and biological products. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2006-01-24
  4 in total
  1 in total

1.  Comparison of the safety information on drug labels in three developed countries: The USA, UK and Canada.

Authors:  Thamir M Alshammari; Venkat Ratnam Devadasu; Rajendra Prasad Rathnam
Journal:  Saudi Pharm J       Date:  2017-07-11       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.